natgillin/translations-raw huggingface dataset:
In the completed uncontrolled study 060103, 16 out of 45 (35.6%) of previously untreated patients with severe haemophilia A (FVIII < 1%) and at least 25 EDs to FVIII developed FVIII inhibitors: 7 (15.6%) subjects developed high-titre inhibitors and 9 (20%) subjects developed low-titre inhibitors, 1 of which was also classified as a transient inhibitor.
V zaključeni nenadzorovani študiji 060103 so se zaviralci faktorja VIII pojavili pri 16 od 45 (35,6 %) predhodno nezdravljenih bolnikih s hudo hemofilijo A (FVIII < 1 %) in z vsaj 25 dnevi izpostavljenosti faktorju VIII: pri sedmih preiskovancih (15,6 %) so se pojavili zaviralci v visokem titru, pri devetih (20 %) pa zaviralci v nizkem titru, od katerih je bil eden razvrščen med prehodne zaviralce.
in the concentration of this
povzroči veliko zvišanje koncentracije tega
In the confirmatory study comparing FIRMAGON to leuprorelin periodic (monthly) electrocardiograms (ECGs) were performed; both therapies showed QT/QTc intervals exceeding 450 msec in approximately 20% of the patients, and 500 msec in 1% and 2% of the degarelix and leuprorelin patients, respectively (see section 5.1).
V potrditveni študiji, v kateri so primerjali zdravilo FIRMAGON z levprorelinom, so snemali periodične (mesečne) elektrokardiograme (EKG-je); pri obeh zdravilih so ugotovili intervale QT/QTc, ki so presegli 450 msek pri približno 20 % bolnikov, pri 1 % na degareliksu oziroma 2 % bolnikov na levprorelinu pa 500 msek (glejte poglavje 5.1).
In the context of signal evaluation activities, the MAH has conducted a search in its safety database of all cases of paraesthesia reported cumulatively until 30 April 2015.
V okviru dejavnosti za vrednotenje signalov je imetnik dovoljenja za promet z zdravilom v svoji zbirki podatkov o varnosti zdravil opravil raziskavo vseh primerov parestezije, ki so bili poročani do vključno 30. aprila 2015.
In the control group and on weeks without Empliciti, dexamethasone 40 mg was administered as a single oral dose weekly.
Bolniki v kontrolni skupini in v tednih brez uporabe zdravila Empliciti so prejemali deksametazon v odmerku 40 mg v obliki enkratnega peroralnega odmerka na teden.
In the controlled and uncontrolled clinical studies of Xiapex in Peyronie’s disease corporal rupture and other serious penile injury were reported uncommonly (see section 4.4)
V nadzorovanih in nenadzorovanih kliničnih študijah z zdravilom Xiapex za Peyroniejevo bolezen so občasno poročali o rupturi korpusa in drugih resnih poškodbah penisa (glejte poglavje 4.4)
In the controlled and uncontrolled periods of pivotal trials with a median follow-up of approximately 2 years, non-melanoma skin cancer was diagnosed in 5 placebo-treated, 10 golimumab 50 mg-treated and 29 golimumab 100 mg-treated subjects with an incidence (95% CI) per 100 subject-years of follow-up of 0.38 (0.27, 0.52) for combined golimumab and 0.90 (0.29, 2.10) for placebo.
V kontroliranih in nekontroliranih obdobjih ključnih preskušanj z medianim trajanjem spremljanja bolnikov do 3 let so diagnozo nemelanomskega kožnega raka postavili pri 5 preiskovancih, ki so prejemali placebo, 10 preiskovancih, zdravljenih s 50 mg golimumaba, in 31 preiskovancih, zdravljenih s 100 mg golimumaba z naslednjima incidencama (95 % IZ) na 100 preiskovanec-let spremljanja: 0,36 (0,26, 0,49) kombinirano za golimumab in 0,87 (0,28, 2,04) za placebo.
In the controlled and uncontrolled periods of RA, PsA and AS pivotal trials, with a median follow-up of 5 years, the incidence of ALT elevations ≥ 5 x ULN was similar in both golimumab-treated and control patients.
V kontroliranih in nekontroliranih obdobjih ključnih preskušanj pri bolnikih z RA in PsA in AS z medianim trajanjem spremljanja bolnikov 5 let je bila incidenca zvišanja vrednosti ALT ≥ 5 x ULN pri bolnikih, zdravljenih z golimumabom, podobna kot pri tistih iz kontrolne skupine.
In the controlled and uncontrolled periods of the pivotal trials with a median follow-up of approximately 2 years, a greater incidence of demyelination was observed in patients receiving golimumab 100 mg compared with patients receiving golimumab 50 mg (see section 4.4).
V kontroliranih in nekontroliranih obdobjih ključnih preskušanj z medianim trajanjem spremljanja bolnikov do 3 let so opazili večjo incidenco demielinizirajočih bolezni pri bolnikih, ki so prejemali golimumab v odmerku 100 mg, kot pri bolnikih, ki so prejemali golimumab v odmerku 50 mg (glejte poglavje 4.4).
In the controlled and uncontrolled periods of the pivotal UC trials with a mean follow-up of 1 year, the incidence of ALT elevations ≥ 5 x ULN was 0.7% in patients receiving golimumab during the maintenance portion of the UC study.
V kontroliranih in nekontroliranih obdobjih ključnih preskušanj pri bolnikih z UK z medianim spremljanjem bolnikov približno 2 leti je bil delež bolnikov z zvišanji ALT na ≥ 5 x ULN 0,8 % pri bolnikih, ki so med vzdrževalnim delom študije UK prejemali golimumab.
In the controlled and uncontrolled portions of the pivotal trials with a median follow-up of approximately 2 years, there was a greater incidence of serious infections, including opportunistic infections and TB in patients receiving golimumab 100 mg compared with patients receiving golimumab 50 mg.
V kontroliranih in nekontroliranih delih ključnih preskušanj z medianim trajanjem spremljanja bolnikov do 3 let je bila incidenca resnih okužb, vključno z oportunističnimi okužbami in tuberkulozo, večja med bolniki, ki so prejemali golimumab v odmerku 100 mg, kot med tistimi, ki so prejemali golimumab v odmerku 50 mg.
In the controlled and uncontrolled portions of these trials with a median follow-up of approximately 2 years, a greater incidence of lymphoma was observed in patients receiving golimumab 100 mg compared with patients receiving golimumab 50 mg.
V kontroliranih in nekontroliranih delih teh preskušanj z medianim trajanjem spremljanja do 3 let, so opazili večjo incidenco limfoma med bolniki, ki so prejemali golimumab v odmerku 100 mg, kot med bolniki, ki so prejemali golimumab v odmerku 50 mg.
In the controlled clinical studies in chronic ITP with eltrombopag, increases in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin were observed (see section 4.8).
V nadzorovanih kliničnih študijah z eltrombopagom pri kronični ITP so poročali o zvišanju vrednosti alanin-aminotransferaze (ALT), aspartat-aminotransferaze (AST) in bilirubina (glejte poglavje 4.8).
In the controlled clinical trial in central neuropathic pain 22% of the pregabalin treated patients and 7% of the patients on placebo had a 50% improvement in pain score.
V kontroliranem kliničnem preskušanju centralne nevropatske bolečine je 22% bolnikov, ki so prejemali pregabalin, in 7% bolnikov, ki so prejemali placebo, izkusilo 50%-no izboljšanje v točkovanju bolečine.
In the controlled clinical trial population, the adverse reaction profile in patients with BMI > 40 (86/1436 or 6%) showed no meaningful difference relative to patients with BMI ≤ 40.
Pri populaciji v nadzorovanih kliničnih preskušanjih profil neželenih učinkov pri bolnikih z ITM > 40 (86/1436 ali 6 %) ni pokazal pomembnih razlik glede na bolnike z ITM ≤ 40.
In the controlled period of RA and AS pivotal trials, ALT elevations ≥ 5 x ULN were uncommon and seen in more golimumab-treated patients (0.4% to 0.9%) than control patients (0.0%).
V kontroliranem obdobju ključnih preskušanj pri bolnikih z RA in AS so bila zvišanja vrednosti ALT ≥ 5 x ULN občasna in so jih več opažali pri bolnikih, zdravljenih z golimumabom (0,4 % do 0,9 %), kot pri tistih iz kontrolne skupine (0,0 %).
In the controlled period of the pivotal trials in RA, PsA, AS, nr-Axial SpA, and UC, upper respiratory tract infection was the most common adverse drug reaction (ADR) reported in 12.6% of golimumab-treated patients compared with 11.0% of control patients.
V kontroliranem obdobju ključnih preskušanj pri bolnikih z RA, PsA, AS, nr-aksialnim SpA in UK je bil najpogostejši neželeni učinek zdravila okužba zgornjih dihal, ki se je pojavila pri 12,6 % bolnikov, zdravljenih z golimumabom, v primerjavi z 11,0 % bolnikov iz kontrolne skupine.
In the controlled period of the UC pivotal trials of golimumab induction, mild ALT elevations (> 1 and < 3 x ULN) occurred in similar proportions of golimumab- treated and control patients (8.0% to 6.9%, respectively).
V kontroliranem obdobju ključnih preskušanj indukcije z golimumabom pri bolnikih z UK se je blago zvišanje ALT (> 1 in < 3 x(ULN)) pojavilo pri podobnem deležu bolnikov, zdravljenih z golimumabom, in bolnikov v kontrolni skupini (8,0 % pri prvih in 6,9 % pri drugih).
In the controlled period of the UC pivotal trials of golimumab induction, mild ALT elevations (> 1 and < 3 x ULN) occurred in similar proportions of golimumab-treated and control patients (8.0% to 6.9%, respectively).
V kontroliranem obdobju ključnih preskušanj indukcije z golimumabom pri bolnikih z UK se je blago zvišanje ALT (> 1 in < 3 x(ULN)) pojavilo pri podobnem deležu bolnikov, zdravljenih z golimumabom, in bolnikov v kontrolni skupini (8,0 % pri prvih in 6,9 % pri drugih).
In the controlled periods of pivotal trials and through approximately 2 years of follow-up, the incidence of non-lymphoma malignancies (excluding non-melanoma skin cancer) was similar between the golimumab and the control groups.
V kontroliranih obdobjih ključnih preskušanj in v času približno 4-letnega spremljanja bolnikov je bila incidenca nelimfomskih malignomov (z izjemo nemelanomskega kožnega raka) pri skupini, ki je prejemala golimumab, podobna kot pri kontrolnih skupinah.
In the controlled periods of the pivotal UC trials, of golimumab induction, ALT elevations ≥ 5 x ULN occurred in similar proportions of golimumab- treated patients compared to placebo-treated patients (0.3% to 1.0%, respectively).
V kontroliranih obdobjih ključnih preskušanj indukcije z golimumabom pri UK so se zvišanja ALT na ≥ 5 x ULN pojavila pri podobnem deležu bolnikov, zdravljenih z golimumabom, in bolnikov, ki so prejemali placebo (0,3 % pri prvih in 1,0 % pri drugih).
In the controlled periods of the pivotal UC trials, of golimumab induction, ALT elevations ≥ 5 x ULN occurred in similar proportions of golimumab-treated patients compared to placebo-treated patients (0.3% to 1.0%, respectively).
V kontroliranih obdobjih ključnih preskušanj indukcije z golimumabom pri UK so se zvišanja ALT na ≥ 5 x ULN pojavila pri podobnem deležu bolnikov, zdravljenih z golimumabom, in bolnikov, ki so prejemali placebo (0,3 % pri prvih in 1,0 % pri drugih).
In the controlled Phase III trials with no-active-treatment follow-up, the incidence of post-treatment ALT elevations (more than 3 times baseline) was higher in lamivudine-treated patients (21%) compared with those receiving placebo (8%).
V kontroliranih preskušanjih III. faze, ki niso obsegala spremljanja brez aktivnega zdravljenja, je bila incidenca zvišanj ALT (na več kot 3- kratnik izhodiščne vrednosti) po zdravljenju večja pri bolnikih, zdravljenih z lamivudinom (21 %), kot pri bolnikih, ki so dobivali placebo (8 %).
In the controlled portions of clinical trials of all the TNF-blocking agents including Simponi, more cases of lymphoma have been observed among patients receiving anti-TNF treatment compared with control patients.
V nadzorovanem delu kliničnih preskušanj z vsemi zaviralci TNF, vključno z zdravilom Simponi, so opazili več primerov limfoma pri bolnikih, ki so se zdravili z zaviralci TNF, kot pri tistih iz kontrolne skupine.
In the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including lymphoma have been observed among patients receiving a TNF-antagonist compared with control patients.
V kontroliranih delih kliničnih preizkušanj z zaviralci TNF je bilo opaženih več primerov malignomov, vključno z limfomi, tako pri bolnikih, ki so prejemali zaviralec TNF, kot pri kontrolnih bolnikih.
In the controlled portions of the Simponi Phase IIb and Phase III clinical trials in RA, PsA, AS, and UC, the incidence of non-lymphoma malignancies (excluding non-melanoma skin cancer) was similar between the Simponi and the control groups.
V nadzorovanem delu kliničnih preskušanj faze IIb in faze III z zdravilom Simponi pri bolnikih z RA, PsA, AS in UK je bila incidenca nelimfomskih malignomov (z izjemo nemelanomskega kožnega raka) pri skupini, ki je prejemala zdravilo Simponi, podobna kot pri kontrolnih skupinah.
In the correction study, haemoglobin levels were around 11.6 g/dl during the last four weeks of the study, having risen from around 8.0 g/dl before treatment.
V študiji popravljanja ravni rdečih krvnih celic so se ravni hemoglobina zvišale s približno 8,0 g/dl pred zdravljenjem na okoli 11,6 g/dl v zadnjih štirih tednih študije.
In the cumulative week 96 pooled resistance analysis for patients receiving rilpivirine in combination with emtricitabine/tenofovir disoproxil fumarate, a greater risk of virologic failure for patients in the rilpivirine arm was observed within the first 48 weeks of these studies (11.5% in the rilpivirine arm and 4.2% in the efavirenz arm) while low rates of virologic failure, similar between the treatment arms, were observed from the week 48 to week 96 analysis (15 patients or 2.7% in the rilpivirine arm and 14 patients or 2.6% in the efavirenz arm).
V kumulativni analizi združenih podatkov v 96. tednu so pri bolnikih, ki so prejemali rilpivirin v kombinaciji z emtricitabinom/dizoproksiltenofovirijevim fumaratom opazili večje tveganje virološkega neuspeha za bolnike v kraku z rilpivirinom v prvih 48 tednih teh študij (11,5 % v kraku z rilpivirinom in 4,2 % v kraku z efavirenzom), medtem ko so v analizah od 48. tedna do 96. tedna opazili nizke stopnje virološkega neuspeha, ki so si bile v krakih zdravljenja podobne (15 bolnikov ali 2,7 % v kraku z rilpivirinom in 14 bolnikov ali 2,6 % v kraku z efavirenzom).
In the current PSUR, a large number of cases includes immediate local ocular tissue irritation, angioedema, urticarial, eczema and allergic dermatitis.
V trenutnem poročilu PSUR veliko število primerov zajema takojšnje draženje lokalnega okularnega tkiva, angioedem, koprivnico, ekcem in alergijski dermatitis.
In the cytokine-pre-treated subgroup, the majority (75 %) had received interferon based treatment.
V podskupini bolnikov, ki so se predhodno že zdravili s citokini, se je večina bolnikov (75 %) zdravila z interferoni.
In the days or weeks after vaccination with vaccines given routinely every year to prevent flu, the side effects listed below have occurred.
Neželeni učinki, ki so se pojavili v dneh ali tednih po vsakoletnem rutinskem cepljenju proti gripi, so navedeni v spodnjem seznamu.
In the de novo liver transplant study, 29 subjects were treated with Envarsus.
V študiji bolnikov z na novo presajenimi jetri je bilo 29 preiskovancev zdravljenih z zdravilom Envarsus.
In the description of the Phase 3 study outcomes for Study C211, HPC3008 and HPC3006, SVR12, considered virologic cure, was defined based on HCV RNA below the limit of quantification (25 IU/ml) using the last measurement in the visit window 12 weeks after the planned end of treatment.
V opisu izidov študij faze III za študiji C211, HPC3008 in HPC3006 je bil SVR12 (virološka ozdravljenost) določen na osnovi ocene HCV RNK pod mejo kvantifikacije (25 i.e./ml) 12. tednov po načrtovanem zaključku zdravljenja, z uporabo zadnje meritve v tem obdobju.
In the dog, changes were observed in the liver and gall bladder at exposures approximately 8-fold higher than human exposure observed at the recommended dose (200 mg b.i.d.).
Pri psih so med jemanjem priporočenega odmerka (200 mg b.i.d.) opažali spremembe v jetrih in žolčniku pri stopnjah izpostavljenosti, ki so bile približno 8-krat večje od stopnje izpostavljenosti pri človeku.
In the Doppler studies, using SonoVue to measure blood flow in large blood vessels improved the quality of the scan when testing the cerebral arteries (in the head), the carotids (in the neck) and the portal vein (leading to the liver), but not the renal arteries (leading to the kidneys).
V študijah z uporabo Dopplerjeve sonografije je uporaba zdravila SonoVue pri meritvah pretoka krvi v velikih krvnih žilah izboljšala kakovost slike pri preiskavah cerebralnih arterij (v glavi), karotid (v vratu) in portalne vene (ki vodi do jeter), ne pa tudi ledvičnih arterij (ki vodijo do ledvic).
In the dose range of 10 to
V razponu odmerkov od 10 do
In the dose range recommended for treatment, the following response rates with the respective confidence intervals have been shown in clinical trials for patients with baseline albumin-corrected serum calcium ≥ 3.0 mmol/l after adequate rehydration.
V razponih odmerkov, priporočenih za zdravljenje, so med kliničnimi preskušanji za bolnike, ki so pred začetkom zdravljenja imeli korigirani kalcij v serumu ≥ 3,0 mmol/l po ustrezni rehidraciji, ugotovili naslednje hitrosti odziva in intervale zaupanja.
In the double blind placebo controlled studies, 529 patients were treated with rasagiline 1 mg/day for 212 patient years and 539 patients received placebo for 213 patient years.
V dvojno slepih, s placebom kontroliranih študijah je bilo 529 bolnikov zdravljenih z razagilinom 1 mg/dan 212 bolnikovih let in 539 bolnikov je prejemalo placebo 213 bolnikov-let.
In the double blind portion of the three phase 3 placebo-controlled clinical studies in Dupuytren’s contracture, 17% of Xiapex-treated patients had mild reactions (i.e. pruritus) after up to 3 injections.
V dvojno slepem delu treh kliničnih študij 3. faze za Dupuytrenovo kontrakturo, ki so bile nadzorovane s placebom, je imelo 17 % bolnikov, zdravljenih z zdravilom Xiapex, blage reakcije (npr. pruritus) po do 3 injekcijah.
In the double-blind controlled studies, 774 patients received tocilizumab 4 mg/kg in combination with MTX, 1870 patients received tocilizumab 8 mg/kg in combination with MTX or other DMARDs and 288 patients received tocilizumab 8 mg/kg monotherapy.
V dvojno slepih, kontroliranih študijah je 774 bolnikov dobivalo 4 mg/kg tocilizumaba v kombinaciji z metotreksatom, 1.870 bolnikov 8 mg/kg tocilizumaba v kombinaciji z metotreksatom oz. drugimi imunomodulirajočimi antirevmatičnimi zdravili, 288 bolnikov pa 8 mg/kg tocilizumaba v monoterapiji.
In the double-blind controlled studies, 774 patients received tocilizumab 4 mg/kg in combination with MTX, 1870 patients received tocilizumab 8 mg/kg in combination with MTX or other DMARDs and 288 patients received tocilizumab 8 mg/kg monotherapy.
V dvojno slepih, kontroliranih študijah je 774 bolnikov dobivalo 4 mg/kg tocilizumaba v kombinaciji z metotreksatom, 1870 bolnikov 8 mg/kg tocilizumaba v kombinaciji z metotreksatom oz. drugimi imunomodulirajočimi antirevmatičnimi zdravili, 288 bolnikov pa 8 mg/kg tocilizumaba v monoterapiji.
In the double-blind portion of the two phase 3 placebo-controlled clinical trials in Peyronie’s disease, a greater proportion of Xiapex-treated patients (4%) compared to placebo-treated patients (1%) had localized pruritus after up to 4 treatment cycles (involving up to 8 Xiapex injections).
V dvojno slepem delu dveh kliničnih preskušanj 3. faze za Peyroniejevo bolezen, ki sta bila nadzorovana s placebom, je imel po do 4 ciklih zdravljenja (vključno z do 8 injekcijami zdravila Xiapex) večji delež bolnikov, zdravljenih z zdravilom Xiapex (4 %) lokalizirani pruritus, v primerjavi z bolniki, zdravljenimi s placebom (1 %).
In the double-blind study SP515, 201 patients received rotigotine, 200 received pramipexole and 100 patients received placebo.
V dvojno slepi študiji SP515je 201 bolnikov prejemalo rotigotin, 200 jih je prejemalo pramipeksol, 100 bolnikov pa je prejemalo placebo.
In the Double-blind, Active-controlled Phase of the 38-week trial, from baseline to last visit there was a mean decrease in prolactin levels in Abilify Maintena (−0.33 ng/ml) compared with a mean increase in oral aripiprazole tablets 10-30 mg (0.79 ng/ml; p < 0.01).
V dvojno slepi aktivno nadzorovani fazi 38-tedenskega preskušanja je bilo od izhodiščne vrednosti do zadnjega obiska srednje zmanjšanje vrednosti prolaktina v skupini, ki je prejemala zdravilo Abilify Maintena, (−0,33 ng/ml) v primerjavi s srednjim povišanjem v skupini, ki je prejemala aripiprazol v 10–30 mg peroralnih tabletah (0,79 ng/ml; p < 0,01).
In the DTC study (see Lenvima SmPC), 88% of all patients had a baseline TSH level less than or equal to
V študiji DTC (glejte SmPC za zdravilo Lenvima) je imelo 88 % vseh bolnikov izhodiščno raven TSH manj kot ali enako 0,5 me./l.
In the DTC study (see Lenvima SmPC), haemorrhage was reported in 34.9% of lenvatinib-treated patients versus 18.3% of placebo-treated patients.
V študiji DTC (glejte SmPC za zdravilo Lenvima) so poročali o krvavitvah pri 34,9 % bolnikov, zdravljenih z lenvatinibom, proti 18,3 % bolnikov, ki so prejemali placebo.
In the DTC study (see Lenvima SmPC), QT/QTc interval prolongation was reported in 8.8% of lenvatinib- treated patients and 1.5% of patients in the placebo group.
V študiji DTC (glejte SmPC za zdravilo Lenvima) so poročali o podaljšanju intervala QT/QTc pri 8,8 % bolnikov, zdravljenih z lenvatinibom, in pri 1,5 % bolnikov v skupini s placebom.
In the Dupuytren’s contracture clinical trials at 30 days post the first injection, 92% of patients had circulating antibodies detected against AUX-I and 86% of patients against AUX-II.
V kliničnih preskušanjih Dupuytrenove kontrakture so po 30 dneh po prvem injiciranju pri 92 % bolnikov zaznali cirkulirajoča protitelesa proti AUX-I in pri 86 % bolnikov proti AUX-II.
In the E/C/F/TAF group, the mutations that emerged were M184V/I (n = 9) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), and N155H (n = 2) in integrase.
V skupini z zdravilom E/C/F/TAF so se pojavile mutacije M184V/I (n = 9) in K65R/N (n = 2) v RT ter T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) in N155H (n = 2) v integrazi.
In the EAP the number of responders increased with longer treatment duration, from 19 out of 62 patients (30.6%) at 6 months to 17 out of 47 patients (36.2%) at 12 months.
Pri EAP se je število odzivnih bolnikov večalo s trajanjem zdravljenja, tj. od 19 izmed 62 bolnikov (30,6 %) po 6 mesecih do 17 izmed 47 bolnikov (36,2 %) po 12 mesecih.
In the early post-transplant period (< 40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 – 6 months post-transplant).
V zgodnjem obdobju po presaditvi (do 40. dneva po presaditvi) je srednja AUC mikofenolne kisline pri bolnikih z ledvičnim, srčnim ali jetrnim presadkom za približno 30 % manjša, Cmax pa za približno 40 % manjša v primerjavi s poznejšim obdobjem po presaditvi (3 do 6 mesecev po presaditvi).
In the early post-transplant period (<°40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and Cmax approximately 40% lower compared to the late post-transplant period (3 – 6°months post-transplant).
V zgodnjem obdobju po presaditvi (do 40. dneva po presaditvi) je srednja AUC mikofenolne kisline pri bolnikih z ledvičnim, srčnim ali jetrnim presadkom za približno 30 % manjša, Cmax pa za približno 40 % manjša v primerjavi s poznejšim obdobjem po presaditvi (3 do 6 mesecev po presaditvi).
In the echocardiography studies, SonoVue was more effective than the comparator and than placebo in improving the clarity of the image obtained of the left ventricle and left ventricle border.
V študijah z uporabo ehokardiografije je bilo pri izboljšanju jasnosti slike levega prekata in roba levega prekata zdravilo SonoVue učinkovitejše od primerjalnega zdravila in placeba.
In the eighth study, a reduction of 0.7% was seen in patients who received triple therapy with saxagliptin, metformin and a sulphonylurea compared with a reduction of 0.1% in patients who were given placebo in place of saxagliptin.
V osmi študiji je bilo opaženo 0,7-odstotno znižanje pri bolnikih, ki so prejemali trojno zdravljenje s saksagliptinom, metforminom in sulfonilsečnino, v primerjavi z 0,1-odstotnim zmanjšanjem pri bolnikih, ki so namesto saksagliptina jemali placebo.